On this page

CICLOPIROX

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
CICLOPIROX
Generic name
Ciclopirox
Dosage form
Gel
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
7
Packages
13
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Ciclopirox 7.7 mg/g 250344 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Gel
Route of administration
Topical
Presentations
20

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased DNA Replication [PE] PE 5 members — no class page
Decreased Protein Synthesis [PE] PE 7 members — no class page
Decreased RNA Replication [PE] PE 5 members — no class page
Protein Synthesis Inhibitors [MoA] MoA 7 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
078266
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 7, 2009
Sponsor
PADAGIS US
Products on application
1
Submissions recorded
2
Products approved under application 078266.
Product Trade name Form Strength Ingredient Status TE Flags
078266-001 CICLOPIROX GEL CICLOPIROX Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 078266.
Type No. Action Status Date Review
Supplement 2 Labeling Approved October 14, 2015 Standard
Original application 1 Approved January 7, 2009 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260123). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260123 HUMAN PRESCRIPTION DRUG · 20241101 HUMAN PRESCRIPTION DRUG · 20230615

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Superficial Dermatophyte Infections Ciclopirox Gel, 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum . Seborrheic Dermatitis Ciclopirox Gel, 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Superficial Dermatophyte Infections Gently massage Ciclopirox Gel, 0.77% into the affected areas and surrounding skin twice daily, in the morning and evening immediately after cleaning or washing the areas to be treated. Interdigital tinea pedis and tinea corporis should be treated for 4 weeks. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed. Seborrheic Dermatitis of the Scalp Apply Ciclopirox Gel, 0.77% to affected scalp areas twice daily, in the morning and evening for 4 weeks. Clinical improvement usually occurs within the first week with continuing resolution of signs and symptoms through the fourth week of treatment. If a patient shows no clinical improvement after 4 weeks of treatment, the diagnosis should be reviewed.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Ciclopirox Gel, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS Ciclopirox Gel, 0.77% is not for ophthalmic, oral, or intravaginal use. Keep out of reach of children.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In clinical trials, 140 (39%) of 359 subjects treated with Ciclopirox Gel, 0.77% reported adverse experiences, irrespective of relationship to test materials, which resulted in 8 subjects discontinuing treatment. The most frequent experience reported was skin burning sensation upon application, which occurred in approximately 34% of seborrheic dermatitis patients and 7% of tinea pedis patients. Adverse experiences occurring between 1% to 5% were contact dermatitis and pruritus. Other reactions that occurred in less than 1% included dry skin, acne, rash, alopecia, pain upon application, eye pain, and facial edema.

Mechanism of Action

openFDA Drug Labeling

Mechanism of Action Ciclopirox is a hydroxypyridone antifungal agent although the relevance of this property for the indication of seborrheic dermatitis is not known. Ciclopirox acts by chelation of polyvalent cations (Fe 3+ or Al 3+ ), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

Description

openFDA Drug Labeling

DESCRIPTION Ciclopirox Gel, 0.77% contains a synthetic antifungal agent, ciclopirox. It is intended for topical dermatologic use only. Each gram of Ciclopirox Gel, 0.77% contains 7.70 mg of ciclopirox in a gel consisting of Purified Water USP, Isopropyl Alcohol USP, Octyldodecanol NF, Dimethicone Copolyol 190, Carbomer 980, Sodium Hydroxide NF, and Docusate Sodium USP. Ciclopirox Gel, 0.77% is a white, slightly fluid gel. The chemical name for ciclopirox is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )- pyridinone, with the empirical formula C 12 H 17 NO 2 and a molecular weight of 207.27. The CAS Registry Number is [29342-05-0]. The chemical structure is: Ciclopirox Gel Structural Formula

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Ciclopirox gel 0.77% is supplied in aluminum tubes and LDPE tubes. 30 g tubes (NDC 68462-455-35), 45 g tubes (NDC 68462-455-47) and 100 g tubes (NDC 68462-455-94). Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888)721-7115 www.glenmarkpharma-us.com April 2025 glenmarklogo

Adverse event reports

Source: openFDA FAERS
2,937
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CICLOPIROX. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8620-1 63629-8620 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8620-1) / 30 g in 1 TUBE January 7, 2009
63629-8621-1 63629-8621 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8621-1) / 45 g in 1 TUBE January 7, 2009
63629-8622-1 63629-8622 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8622-1) / 100 g in 1 TUBE January 7, 2009
71335-2757-1 71335-2757 Bryant Ranch Prepack 30 g in 1 TUBE (71335-2757-1) August 8, 2025
72162-1126-1 72162-1126 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1126-1) / 100 g in 1 TUBE March 11, 2024
72162-1126-2 72162-1126 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1126-2) / 45 g in 1 TUBE March 11, 2024
72162-1126-3 72162-1126 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1126-3) / 30 g in 1 TUBE March 11, 2024
68462-455-35 68462-455 Glenmark Pharmaceuticals Inc., USA 30 g in 1 TUBE (68462-455-35) February 29, 2012
68462-455-47 68462-455 Glenmark Pharmaceuticals Inc., USA 45 g in 1 TUBE (68462-455-47) February 29, 2012
68462-455-94 68462-455 Glenmark Pharmaceuticals Inc., USA 100 g in 1 TUBE (68462-455-94) February 29, 2012
0574-2061-01 0574-2061 Padagis US LLC 1 TUBE in 1 CARTON (0574-2061-01) / 100 g in 1 TUBE January 7, 2009
0574-2061-30 0574-2061 Padagis US LLC 1 TUBE in 1 CARTON (0574-2061-30) / 30 g in 1 TUBE January 7, 2009
0574-2061-45 0574-2061 Padagis US LLC 1 TUBE in 1 CARTON (0574-2061-45) / 45 g in 1 TUBE January 7, 2009
63629-8620 63629-8620 Bryant Ranch Prepack — January 7, 2009
63629-8621 63629-8621 Bryant Ranch Prepack — January 7, 2009
63629-8622 63629-8622 Bryant Ranch Prepack — January 7, 2009
71335-2757 71335-2757 Bryant Ranch Prepack — February 29, 2012
72162-1126 72162-1126 Bryant Ranch Prepack — January 7, 2009
68462-455 68462-455 Glenmark Pharmaceuticals Inc., USA — February 29, 2012
0574-2061 0574-2061 Padagis US LLC — January 7, 2009

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.